Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen

European Journal of Clinical Investigation

Volumn 44, Issue 8, 2014, Pages 753-765

  Škoberne, Andrej ^a,b   Behnert, Astrid ^a   Teng, Beina ^a   Fritzler, Marvin J ^c   Schiffer, Lena ^a   Pajek, Jernej ^b   Lindič, Jelka ^b   Haller, Hermann ^a   Schiffer, Mario ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Cell adhesion; Collagen IV; PLA2R antibodies; Podocyte; Primary membranous nephropathy

Indexed keywords

ALPHA2 INTERFERON; AUTOANTIBODY; COLLAGEN TYPE 4; EOTAXIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FLT3 LIGAND; FRACTALKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; INTERLEUKIN 9; PHOSPHOLIPASE A2 RECEPTOR; PHOSPHOLIPASE A2 RECEPTOR AUTOANITBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CELL ADHESION; CELL ADHESION ASSAY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXTRACELLULAR MATRIX; FEMALE; FOCAL ADHESION; GENETIC TRANSFECTION; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PODOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEINURIA; WESTERN BLOTTING; CASE CONTROL STUDY; HEK293 CELL LINE; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SERUM; YOUNG ADULT;

ADULT; AGED; AUTOANTIBODIES; CASE-CONTROL STUDIES; CELL ADHESION; COLLAGEN TYPE IV; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HEK293 CELLS; HUMANS; MALE; MIDDLE AGED; PODOCYTES; RECEPTORS, PHOSPHOLIPASE A2; SERUM; YOUNG ADULT;

EID: 84904556287     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12292     Document Type: Article

References (30)

1. Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21.
2. Glassock RJ. The pathogenesis of membranous nephropathy: evolution and revolution. Curr Opin Nephrol Hypertens 2012;21:235-42.
3. Hofstra JM, Wetzels JF. Anti-PLA R antibodies in membranous nephropathy: ready for routine clinical practice? Neth J Med 2012;70:109-13.
4. East L, Isacke CM. The mannose receptor family. Biochim Biophys Acta 2002;1572:364-86.
5. Ancian P, Lambeau G, Mattei MG, Lazdunski M. The human 180-kDa receptor for secretory phospholipases A2. Molecular cloning, identification of a secreted soluble form, expression, and chromosomal localization. J Biol Chem 1995;270:8963-70.
6. Hanasaki K, Arita H. Phospholipase A2 receptor: a regulator of biological functions of secretory phospholipase A2. Prostaglandins Other Lipid Mediat 2002;68-69:71-82.
7. Granata F, Petraroli A, Boilard E, Bezzine S, Bollinger J, Del Vecchio L et al. Activation of cytokine production by secreted phospholipase A2 in human lung macrophages expressing the M-type receptor. J Immunol 2005;174:464-74.
8. Silliman CC, Moore EE, Zallen G, Gonzalez R, Johnson JL, Elzi DJ et al. Presence of the M-type sPLA(2) receptor on neutrophils and its role in elastase release and adhesion. Am J Physiol Cell Physiol 2002;283:C1102-13.
9. Hoxha E, Kneißler U, Stege G, Zahner G, Thiele I, Panzer U et al. Enhanced expression of the M-type phospholipase A2 receptor in glomeruli correlates with serum receptor antibodies in primary membranous nephropathy. Kidney Int 2012;82:797-804.
10. Lambeau G, Lazdunski M. Receptors for a growing family of secreted phospholipases A2. Trends Pharmacol Sci 1999;20:162-70.
11. Ancian P, Lambeau G, Lazdunski M. Multifunctional activity of the extracellular domain of the M-Type (180 kDa) membrane receptor for secretory phospholipases A2. Biochemistry 1995;34:13146-51.
12. Stahl R, Hoxha E, Fechner K. PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. N Engl J Med 2010;363:496-8.
13. Hofstra JM, Beck LH Jr, Beck DM, Wetzels JF, Salant DJ. Anti-phospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011;6:1286-91.
14. Hofstra JM, Debiec H, Short CD, Pellé T, Kleta R, Mathieson PW et al. Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. J Am Soc Nephrol 2012;23:1735-43.
15. Kanigicherla D, Gummadova J, McKenzie EA, Roberts SA, Harris S, Nikam M et al. Anti-PLA2R antibodies measured by ELISA predict long-term outcome in a prevalent population of patients with idiopathic membranous nephropathy. Kidney Int 2013;83:940-8.
16. Beck LH Jr, Fervenza FC, Beck DM, Bonegio RG, Malik FA, Erickson SB et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011;22:1543-50.
17. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-12.
18. Behnert A, Fritzler MJ, Teng B, Zhang M, Bollig F, Haller H et al. An anti-phospholipase A2 receptor quantitative immunoassay and epitope analysis in membranous nephropathy reveals different antigenic domains of the receptor. PLoS ONE 2013;8:e61669.
19. Taherian A, Li X, Liu Y, Haas TA. Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 2011;11:293.
20. Murphy DA, Courtneidge SA. The 'ins' and 'outs' of podosomes and invadopodia: characteristics, formation and function. Nat Rev Mol Cell Biol 2011;12:413-26.
21. Schell C, Baumhakl L, Salou S, Conzelmann AC, Meyer C, Helmstädter M et al. N-WASP Is Required for Stabilization of Podocyte Foot Processes. J Am Soc Nephrol 2013;24:713-21.
22. Chen S, Wassenhove-McCarthy D, Yamaguchi Y, Holzman L, van Kuppevelt TH, Orr AW et al. Podocytes require the engagement of cell surface heparan sulfate proteoglycans for adhesion to extracellular matrices. Kidney Int 2010;78:1088-99.
23. Sachs N, Sonnenberg A. Cell-matrix adhesion of podocytes in physiology and disease. Nat Rev Nephrol 2013;9:200-10.
24. Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA et al. Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. J Am Soc Nephrol 2000;11:669-83.
25. Dähnrich C, Komorowski L, Probst C, Seitz-Polski B, Esnault V, Wetzels JF et al. Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy. Clin Chim Acta 2013;421:213-8.
26. Lelongt B, Legallicier B, Piedagnel R, Ronco PM. Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? Curr Opin Nephrol Hypertens 2001;10:7-12.
27. Akiyama K, Shikata K, Sugimoto H, Matsuda M, Shikata Y, Fujimoto N et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Res Commun Mol Pathol Pharmacol 1997;95:115-28.
28. Bauvois B, Mothu N, Nguyen J, Nguyen-Khoa T, Nöel LH, Jungers P. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis. Nephrol Dial Transplant 2007;22:1115-22.
29. Zakiyanov O, Kalousová M, Kratochvilová M, Kríha V, Zima T, Tesar V. Changes in levels of matrix metalloproteinase-2 and -9, pregnancy-associated plasma protein-A in patients with various nephropathies. J Nephrol 2013;26:502-9.
30. Augert A, Payré C, de Launoit Y, Gil J, Lambeau G, Bernard D. The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep 2009;10:271-7.